A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2016
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis; Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 25 Aug 2016 Status changed from recruiting to completed.
- 15 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016.
- 15 Jun 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2016.